. 2020 Jan 31;7(2):ofaa035. doi: 10.1093/ofid/ofaa035

Table 2.

Comparison of Laboratory Results Among all Patients Before and After Treatment

	IVCY Group (n = 11)			RTX Group (n = 6)
	Active	Remission	P - Value	Active	Remission	P - Value
Basic investigations (normal range)
WBC (4.00–10.00), ×10³/cumm	20.12 (17.13–38.61)^a	7.55 (4.16–10.91)^a	<.001*	14.77 (10.80–36.62)^a	7.60 (5.11–9.23)^a	.007*
Neutrophils (40.00–74.00), %	78.23 (±9.92)^b	44.78 (±8.27)^b	<.001*	67.40 (±10.07)^b	52.57 (±9.53)^b	.013*
Hemoglobin (12.00–16.00), g/dL	9.80 (±1.69)^b	12.40 (±1.34)^b	<.001*	8.75 (±1.95)^b	11.99 (±1.05)^b	.050*
Platelets (140.0–450.0), ×10³/cumm	478.00 (358–654)^a	273.00 (172–412)^a	<.001*	247.00 (105–821)^a	223.00 (179–291)^a	.417
ESR (4.0–20.0), mm/h	97.78 (±25.69)^b	47.95 (±18.00)^b	<.001*	91.14 (±11.04)^b	52.00 (±18.99)^b	.004*
C-reactive protein (<5), mg/dL	37.63 (8.08–272.00)^a	3.34 (1.00–17.63)^a	<.001*	57.45 (4.26–99.28)^a	3.02 (1.59–4.68)^a	.009*
Serum albumin (35–50) (±SD), g/L	28.85 (±6.44)^b	38.55 (±2.64)^b	<.001*	25.46 (±8.52)^b	35.55 (±1.62)^b	.333
Alkaline phosphatase (40–150), U/L	135.0 (83–671)^a	84.5 (36.7–154.0)^a	.016*	405.0 (112.00–1191.0)^a	71.0 (57.0–108.0)^a	.012*

Abbreviations: ESR, erythrocyte sedimentation rate; IQR, interquartile range; IVCY, intravenous cyclophosphamide; RTX, rituximab; WBC, white blood cell count.

^aMedian (IQR).

^bMean (SD).